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48 Poster Session-Ihas not been identified at the time of this report. Five patients are
alive (3–13 mo) while 1 patient died 12 mo. after CBT due to pneu-
monia.
Conclusion: Preliminary analysis suggests that ex vivo EXP in
MSC-CB is feasible and may provide rapid engraftment. Accrual
to the trial continues.123
CD41FOXP31 REGULATORY T CELLS MEDIATE SUPPRESSION OF COL-
ONY FORMING ACTIVITY OF LEUKEMIC AS WELL AS PRIMARY MYELOID
PROGENITORS
Urbieta, M., Levy, R.B. University of Miami Miller School of Medicine,
Miami, FL
CD41CD251Foxp31 regulatory T cells (Treg) are essential
intermediaries of peripheral self tolerance. The role of Treg as mod-
ulators of the adaptive and innate immune responses has been exten-
sively studied within the last decade. Our laboratory has previously
found that in addition to their ability to regulate such responses,
Treg cells also possess the capacity to inhibit the colony forming ac-
tivity of early hematopoietic progenitor cells (PC) of myeloid origin.
In vitro experiments demonstrated that co-cultures of bone marrow
PC with activated Tregs resulted in 60% decrease of CFU-IL3
levels. Suppression of CFU activity was contact dependent and in-
volved TGF-b1, a Treg cytokine with strong inhibitory properties
of early hematopoietic progenitors. To address the regulation by
Tregs on bone marrow PC in vivo, highly purified (.99.5%) Tregs
from B6-Foxp3gfp1 mice were co-infused with syngeneic bone
marrow into lethally irradiated, B6-wt recipients. Colony forming
activity of IL-3 sensitive myeloid progenitors was assessed one
week post-BMT and was significantly suppressed (p\0.02) in recip-
ients receiving co-infused Treg cells. Based on the ability to suppress
differentiation of primary hematopoietic PC populations, we hy-
pothesized that Tregs may also inhibit myeloid leukemia progenitor
populations. To test this hypothesis, the myeloid leukemia cell line
NFS-60 was examined. The expression of IL-3Ra on these leukemia
cells was confirmed by flow cytometry, consistent with their IL-3 de-
pendence for growth and survival. We co-cultured anti-CD3/CD28
activated Treg cells with NFS-60 cells for 2 days and examined their
CFU activity in rmIL3 supplemented methylcellulose cultures. Acti-
vated Tregs suppressed CFU levels  70%. This inhibition was
abolished in transwell cultures indicating the Treg effector activity
was contact dependent as observed for primary marrow progenitor
cell suppression. Addition of rTGF-b1 inhibited NSF-60 prolifera-
tion and experiments involving neutralization of bioactive TGF-b1
in Treg/NFS-60 co-cultures with mAb 1D11 are presently under-
way. We intend to investigate myeloid progenitor cell activity and
tumor cell proliferation in leukemia bearing recipients receiving au-
tologous hematopoietic cell transplants (HCT) together with Treg
populations.HISTOCOMPATIBILITY/ALTERNATIVE STEM
CELL SOURCES
124
HIGH RISK OF GRAFT FAILURE IN PATIENTS WITH ANTI-HLA ANTI-
BODIES UNDERGOING HAPLOIDENTICAL STEM CELL TRANSPLANTA-
TION
Ciurea, S.O., de Lima, M., Cano, P., Korbling, M., McMannis, J.,
Giralt, S., Shpall, E.J., Champlin, R.E., Fernandez-Vina, M. The
University of Texas M.D. Anderson Cancer Center, Houston, TX
Background: Haploidentical stem cell transplantation
(HaploSCT) is associated with a graft failure (GF) rate of up to
20%, the causes of which are currently unknown. We hypothesized
that anti-HLA antibodies (HLA AB) directed against donor specific
antigens are contributing to the development of GF in such patients.
Methods: 22consecutivepatients,who receiveda total of 25haploi-
dentical transplants, were evaluated prospectively for the presence of
HLAAB.The conditioning regimen consisted offludarabine,melpha-
lan and thiotepa previously described. The presence of antibodies wasdetermined by testing the patients’ sera with a panel of fluorescent
beads coated with single HLA antigens using a Luminexe platform;
results were interpreted as fluorescence intensity (FI) with FI\500
negative, and 500–1500, 1500–3000 and.3000 considered weak, in-
termediate and strong, respectively. HLA A, B, C, DRB1, DRB3/4/
5, DQB1 and DPB1 were typed by high resolution methods.
Results: 6/22 patients experienced GF. Five patients, all females
with median age 39 years, had intermediate or strong FI antibody
titers, directed against both HLA class I and II antigens, most com-
monly anti-HLA DRB1. Overall, 4/6 (67%) HaploSCT performed
in the in the presence of HLA AB developed GF as compared with
1/19 (5%) patientswhodid not have antibodies (P5 0.001).Moreover,
all 4 patients (100%) receiving aHaploSCT in the presence ofmoder-
ate to high DSA titers failed to engraft (Table). Patients with GF un-
derwent second transplants from the same donors. After the first
patient was identified to have GF in the presence of HLA antibodies,
treatmentwith rituximab andplasma exchangewas initiated; this treat-
ment appeared todecrease the antibody titers in 2/4patients enough to
allow engraftment (Table). No significant differences were found in
the #CD341 cells infused, # allelemismatched, and # of bonemarrow
blasts at the time of transplant between the two groups. A review of the
pregnancy history (all patients with HLA antibodies were females)
showed that themedian number of pregnancies was 3 in theGF group
(N5 5) as compared with 0 in the control group (N5 6) (P5 0.1). In
addition, the transfusion history identified a median of 37 units (range
17–65) transfused in the GF group (N 5 5) as compared with 15 the
control group (range 4–38) (N5 16) (P5 0.007).
Conclusion: A high rate of graft rejection was observed among
patients with donor-derived anti-HLA antibodies receiving
a HaploSCT.
Relationship between HLA antibody titers and engraftment in
5 patients who received a total of 8 haploidentical transplants
at MDACC
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FLUDARABINE, MELPHALAN AND THIOTEPA CONDITIONING FOR UNRE-
LATED DONOR CORD BLOOD TRANSPLANTATION
Ciurea, S.O., Kebriaei, P., Khouri, I., Qazilbash, M., Jones, R.,
Petropoulos, D., Worth, L.L., Alousi, A., Hosing, C., Cano, P.,
McMannis, J., Giralt, S., Fernandez-Vina, M., Shpall, E.J., de
Lima,M. University of TexasMDAnderson Cancer Center, Houston, TX
Cord blood transplantation (CBT) is an established therapy for
patients (pts) who lack a matched sibling or unrelated donor. How-
ever, the optimal type and intensity of the preparative regimen for
such pts is unclear. We studied a conditioning regimen consisting
of fludarabine, melphalan and thiotepa in adult pts receiving a CBT.
Methods: 37 pts, median age 31 years (2–57), median weight
73kg, with advanced hematologic malignancies (24 with acute leuke-
mia, 13 with lymphoma/CLL) were treated between 8/2003-5/2008.
Poster Session-I 49At the time of transplant, 21 pts (57%) were in complete remission
(CR) (CR1 5 20%) and 16 had relapsed/refractory disease. Grafts
consisted of double (29 pts) or single (8 pts) CB units. Donor recip-
ientHLAmatching (n5 66 units) was 3/6 (n5 1, 1.5%), 4/6 (n5 47,
71.2%) and 5/6 (n 5 18, 27.3%) alleles. Median TNC infused was
1.8  107/kg (range 1–5.8). 19 pts received ex-vivo expanded units.
The conditioning regimen consisted of melphalan 140 mg/m2 on
day -8, thiotepa 10 mg/m2 on day -7, fludarabine 160 mg/m2 over
4 days on days -6 to -3, and rabbit ATG 1.25 mg/kg on day -4 and
1.75 mg/kg on day -3 (FMT). Patients with CD 201 lymphoid ma-
lignancies also received rituximab 375mg/m2 on day -9 (n5 8, 22%).
GVHD prophylaxis was tacrolimus and mini-methotrexate in 23
(62%) and tacrolimus and mycophenolate in 14 pts (38%).
Results: 34/36 evaluable pts (95%) engrafted neutrophils and had
hematopoietic recovery with 100% cord blood-derived cells. At day
30, of the 29 pts who received a double CBT, 75% had chimerism
derived entirely from one donor while 25% had mixed donors chi-
merism. Neutrophil recovery occurred after a median of 21 days
(range 6–45) and platelet recovery after a median of 37 days (range
26–134, N5 24; 67%). 32/37 pts (87%) were in CR after transplant
with 16 surviving after a median follow-up of 12.1 months. Thirteen
pts (36%) developed gr II-IV aGVHD (gr III-IV aGVHD in 5 pts,
14%), and 13 of 32 pts had cGVHD (40%), with the majority expe-
riencing extensive GVHD. 11 pts (29.7%) relapsed after a median of
7 months post transplant and 12 died of non-relapse causes. Day-100
treatment-related mortality (TRM) in this heavily pre-treated
population was 10%. Overall, causes of death included disease
relapse (n 5 9), infections (n 5 6), organ failure (n 5 3), pulmonary
hemorrhage (n 5 1) and GVHD (n 5 2).
Conclusions: The FMT regimen is associated with a high rate of
engraftment and low TRM in adult pts undergoing CBT which
supports its further evaluation in CBT.126
ALTENATIVE DONOR PERIPHERAL STEM CELL TRANSPLANT (PSCT)
WITH CD31 DEPLETION AND CD31 ADDBACK FOR PEDIATRIC
PATIENTS WITH LEUKEMIAS
Bunin, N.1, Grupp, S.1, Aplenc, R.1, Brown, V.1, Monos, D.2, Pierson, G.2
1The Childrens Hospital of Philadelphia, Philadelphia, PA; 2
Most patients (pts) with leukemias who may benefit from alloge-
neic HSCT lack matched related donors (MRD), and due to diverse
ethnic backgrounds, matched unrelated donors may be unavailable
in a timely fashion. High doses of mobilized PSCs may decrease
time to engraftment and relapse risk, but most studies report an in-
creased risk of extensive chronic GVHD. Partial T depletion allows
the use of alternative donors, while potentially retaining graft vs leu-
kemia(GVL) effect and ensuring engraftment. We began a pilot
study in 2005 for pts with leukemias or myelodysplastic syndromes
who lacked MRD using CD31 depleted PSCs with a defined dose
of CD31 at the time of infusion. Conditioning included thiotepa
5mg/kg  2 d, cyclophosphamide 60 mg/kg  2 d, TBI 1200 cGy.
Clinimacs device was used for CD31 depletion, and an aliquot of in-
tact PSCs was cryopreserved for potential donor lymphocyte infu-
sion (DLI). GVHD prophylaxis included cyclosporine followed by
oral tacrolimus. Initial CD31 dose was 0.2 105/kg, but this was es-
calated to a maximum of 5 105/kg depending uponHLA disparity.
This report includes the first 28 pts with at least 6 months follow up
(median, 18 months, 9–41). Patients included 17 males, median age
12 years (0.8–20). Diagnoses included ALL -13, AML - 6, MDS/
MPD-5, JMML-1,CML-3. Donors were unrelated for 25, and re-
lated (father, brother, aunt) for 3. Donors were high resolution 10/
10 matched for 8 pts (30%); 7 had single antigen or allele mis-
matches, 9 had 2 mismatches and 4 had 3. Pts received a median of
5  106/kg CD341 (3–10) and a median of 1.8  105/kg CD31
(0.5–8). Engraftment occurred in all pts, with ANC.500 at a median
of 16 days (10–26) and platelets.20k at a median of 13 days (8–28).
Acute GVHD occurred in 17 pts, and was overall grade I-II in 14,
III-IV in 3 (10.7%) Chronic GVHD developed in 7/24 evaluable
pts (29%) and was extensive in 4 (17%). TRM occurred in 5 pts be-
fore d1175 from ARDS (1), liver failure/VOD (2), invasive fungus
(1) and GVHD/MSOF (1). Relapses occurred in 5 pts (ALL-3,
AML/MPD-2) at 3- 12months and 2CMLpts developedmixed chi-
merism. Three pts with AML, MPD, and CML who received DLI
have full donor chimerism 24–41 months post SCT. EFS is 57%and OS 68 % including pts in remission following DLI. CD31 de-
pletion with a defined dose of CD31 provides durable engraftment,
maintains GVL, and allows use of mismatched donors. Additional
study is needed to define optimal dose and type of T cell addback.127
THE IMPORTANCE OF BLOOD CYCLOSPORINE LEVEL DURING FOUR
WEEKS AFTER UNRELATED CORD BLOOD TRANSPLANTATION TO PRE-
VENT SEVERE GRAFT-VERSUS-HOST DISEASE
Tsukada, N.1, Takahashi, S.1, Ooi, J.1, Tomonari, A.1, Mae, H.1,
Konuma, T.1, Kato, S.1, Sato, A.1, Kasahara, S.1, Monma, F.1, Oiwa-
Monna, M.1, Asano, S.2, Tojo, A.1 1 Institute of Medical Science, The
University of Tokyo, Minato-ku, Tokyo, Japan; 2Waseda University,
Shinjuku-ku, Tokyo, Japan
We studied the clinical outcomes of 113 adults with hematologic
malignancies who received unrelated cord blood transplantation
(CBT) after myeloablative preparative regimens including 12 Gy to-
tal body irradiation. All patients received same graft-versus-host dis-
ease (GVHD) prophylaxis consisted of cyclosporine (CsA; 3mg/kg
intravenous infusion over 10 hours) and short-term methotrexate
(MTX; 15mg/m2 on day1 and 10mg/m2 on days 3 and 6). CsA was
reduced due to impaired renal function or was tapered beginning
betweenweeks 6 and 9 in the absence ofGVHD in our protocol.Me-
dian number of nucleated cells in infused cord blood was 2.37 107/
kg (range 1.73 to 5.29 107/kg). Cord blood grafts weremismatched
0 to 4 of 6 HLA-A, -B (antigen level), and -DRB1 (allele level) to the
recipient. Engraftment was achieved in 105 of 113 patients and those
were subjected to be analyzed for acute GVHD.Of the 105 evaluable
patients, the incidence of grade II to IV and III to IV acute GVHD
was 62.9 % and 8.6 %, respectively. Ninety five patients survived
more than 100 days and extensive type chronic GVHD occurred in
24.2 %. Of the 113 patients, 72 were alive and disease-free between
333 and 3658 days after CBT (median 1558 days). In 105 evaluable
patients, median day of tapering and 50% reduction of CsA was 28
(range 0 to 110) days and 39 days (range 4 to 142) after transplanta-
tion, respectively. The average of trough CsA level after 1 week, 2
weeks, 3 weeks, and 4 weeks was 177, 149, 160, and 166 ng/ml,
respectively. In 54 of 105 patients, trough CsA levels were more
than 160 ng/ml on day 28 and none had grade III to IV acute
GVHD. The incidence of extensive type chronic GVHD was 13.7
% in 51 evaluable patients whose trough CsA levels were more
than 160ng/ml on day 28. These results suggested that cyclosporine
and short-term MTX effectively prevented the occurrence of severe
GVHD after myeloablative CBT and blood CsA levels should be
monitored carefully during early phase after transplantation.128
ANTIBODIES ARE DETECTED AGAINST MISMATCHED HLA CLASS II AL-
LELES AND NOT CLASS I FOLLOWING ALLOGENEIC HEMATOPOIETIC
CELL TRANSPLANTATION
Arai, S.1, Tyan, D.1, Vayntrub, T.1, Vail, S.1, Hassebroek, A.2, Brady, C.3,
Spellman,S.3,Miklos,D.1 1StanfordUniversity, Stanford, CA; 2CIBMTR,
Minneapolis, MN; 3National Marrow Donor Program, Minneapolis, MN
This pilot study sought to determine whether alloantibody to
HLA is made in patients with acute GVHD. Day 100 serum samples
of 40 recipient-donor pairs of (theoretically) single antigen/allele
HLA-mismatched (MM) unrelated donor transplants performed be-
tween July 1990 and June 1999 were obtained in collaboration with
the CIBMTR and NMDP. All recipients had developed acute
GVHD. We measured HLA class I and II antibody (Ab) levels to
the MM alleles in both the graft-versus-host (GVH) and host-
versus-graft (HVG) directions. Allele level typing for eight loci (A,
B, C, DRB1, DQB1, DQA1, DPB1, DPA1) was compared between
donor and recipient to identify all mismatches. GVHdisparitymeant
the allele expressed in the recipient was absent in the donor. HVG
disparity meant the allele expressed in the donor was absent in the re-
cipient. In general, we observed more than a single allele MM in
these pairs. Sera were screened for IgG antibody to the MM HLA
alleles using single antigen beads covering 96 different class I
